FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene.
BRAF-Targeted Drug Approved for Pediatric Low-Grade Glioma
Posted in biotech/medical
Posted in biotech/medical
FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene.